OLMEZEST-H
Manufacturer DetailsSUN PHARMA
Olmesartan medoxomil 20mg, Hydrochlorthiazide 12.5mg tabs,
| Strength | Rate | Packing Style |
|---|---|---|
| 20mg+12.5mg | 111.00 | 10s tablets |
List of Related Indications:
- Hypertension
List Of Drugs:
- Olmesartan medoxomil - @ - Angiotensin II antagonists- (FDC- List )- (May 2006)
Indication Type Description:
Drug Interaction
Indication
Adverse Reaction
Contra-Indications
Dosages/ Overdosage Etc
Patient Information
Pharmacology/ Pharmacokinetics
Interaction with Food
Drug Interaction:
Angiotensin II Receptor Antagonists-
Candesartan, Eposartan, Irbestan, Losartan metabolite, Olmestran, Telmistran, Valsartan
Potassium supplements, potassum sparing diuretics,
NSAIDS, Lithium
Indication:
Angiotensin II Receptor Antagonists-
Candesartan, Eposartan, Irbestan, Losartan metabolite, Olmesatran, Telmistran, Valsartan
INFORMATION UPDATE- RISKY
OLMESETRON - HELPFUL BUT RISKY
Olmesetron( sold as OLMETOR, OLMEZEST-H etc.) an angiotensin -receptor blocker, delays the development of mcroalbuminuria in patients with type II diabetes and well controlled blood pressure, but its use is associated with increased risk of death from cardiovascular events, according to New England Journal of Medicine study.
- The ROADMAP trial , sponsored by the drug manufacturer , randomised some 4500 diabetic patients with normalalbulminuria to daily Olmesetron palcebo. In addition, particpants blood pressure were treated to maintain values under 130/80 mm Hg. After a median 3 year follow up the olmesetron group showed a significant advantage over placebo in delaying time to onset of microalbuminuria( the primary outcome). However, fatal cardiovascular events were common with olmesetron
Adverse Reaction:
Angiotensin II Receptor Antagonists-
Candesartan, Eposartan, Irbestan, Losartan metabolite, Olmesatran, Telmistran, Valsartan
OLMESATRAN
CNS -
Dizziness 3% ,Insomnia >0.5%, Headache >1% ,Fatigue > 0.5%
GI -
Diarrhea >1%,Dyspepsia/heartburn 0.5%, Abdominal pain >0.5%
Musculoskeletal-
Arthalgia .0.5% Pain >1%, Myalgia > 0.5%
Respiratory -
Upper Res tract infn >1% Sinusitis >1% Pharyngitis >1 Rhinitis >1%
Influnz symptoms >1% bronchitis>1%
Miscellaneous -
Chest pain > 0.5% Rash > 0.5% Tacycardia > 0.5% Urinary tract infn > 0.5%
Peripheral edema > 0.5% Hypertriglyceridemia >1%
Creatinine phosphokinase increase >1% Hyperglycemia >1% Hematutia >1%
Infected injury >1%
Contra-Indications:
Pregnancy, lactation, billiary obstruction
Special precautions-
Intrmuscular volume depletion Conditions which stimulates rennin angiotensin aldersterone system.
Renovascular hypertension
Renal impairment and kidney transplantation
Hyperkalemia Aortic or mitral valve stenosis
Obstructive hypertropic cardiomyopathy Primary aldosteronism
Hepatic impairment
Excessive blood pressure decrease in patients with ischemic heart disease or ischemic cerbrovascular disease could result in myocardial infraction or stroke
Dosages/ Overdosage Etc:
Indication
Hypertension
Dosage
Hyperstension- 20mg once daily when used as monotherapy in patients who are not volume contracted
After 2 weeks of therapy the dose of olmesartan may be increased to 40mg .
Doses above 40mg do not appear to have greater effect
Twice daily dosing offers no advantage over the same total dose given once daily
Patient Information:
Angiotensin II Receptor Antagonists-
Candesartan, Eposartan, Irbestan, Losartan metabolite, Olmestran, Telmistran, Valsartan
Pharmacology/ Pharmacokinetics:
Pharmacology-
Olmesartan acheves blood pressure reduction in dose dependent manner thruough arterial vasodilation and reduced sodium retention
Pharmacokinetics-
Olmesartan showsl inear pharmcokinetics after single oral dose of upto 350mg and multiple oral doses of up to 80mg >The mean oral biavailability in healthy adult volunteers was 29% .
The median peak mean elmination half-lfe was approx 14-16 hrs. with a duraton of upto 24 hrs Olmesartan is not metabolised via the cytochrome P450 enzymes system and so is not affected by food nor it does affect drugs.
Interaction with Food:
Olmersartan may be administered with or without food.
